PhD Scientific Days 2021

PH_I_P: Pharmaceutical Sciences I. Posters

Synergy of Bortezomib and TIC10 in melanoma in vitro

Előadó neve

Dr. Takács, Angéla

Előadó munkahelye

Department of Genetics, Cell and Immunobiology

Előadó telefonszáma

36206701511

Előadó e-mail címe

angela.takacs1@gmail.com

Az előadás címe

Synergy of Bortezomib and TIC10 in melanoma in vitro

Szerző(k) neve és munkahelye

Angela Takacs
Department of Genetics, Cell and Immunobiology, Budapest

Bemutatás módja

Poszter

Szekció

Pharmaceutical Sciences I. Posters

Language of the presentation

Hungarian

Preferred session

Pharmaceutical Sciences

Összefoglaló szövege

Combination antitumor treatments are essential parts of modern tumor therapy as – compared to monotherapies – (i) they are more effective; (ii) the dose of the compounds can be reduced; (iii) therefore the side effects are improved. Our research group previously demonstrated the antitumor character of bortezomib (BOZ) in A2058 melanoma cells. Unfortunately, dose-related side effects are common during BOZ therapy, which could be prevented by reducing the dose of BOZ. This study aims to characterize synergistic combinations of BOZ with TRAIL-inducing compound (TIC10), where the doses can be cut down but the efficacy is preserved. Endpoint cell viability assays were performed on A2058 cells and synergism of BOZ and TIC10 was observed after 72h. Synergism was further validated in real-time impedimetric assay and our results showed, that BOZ treated melanoma cells survived the treatment, which effect was not registered in the co-treatments. Treatment with the combinations resulted in increased apoptosis, which was not accompanied by enhanced cytotoxicity observed in an LDH assay. Nevertheless, the expression of death receptor 5 (DR5) was increased on the cell surface without transcriptional regulation. In summary, our findings support the theory that the application of BOZ and TIC10 in combination could provide higher efficacy in vitro.
This research was funded by National Competitiveness and Excellence Programme
(NVKP_16-1-2016-0036), by the ÚNKP-19-3-I-SE-49 New National Excellence Program of the
Ministry for Innovation and Technology and by the EFOP-3.6.3-VEKOP-16-2017-00009 program.

University and Doctoral School

Semmelweis University, Doctoral School of Pharmaceutical Sciences

Supervisor

Dr. Eszter Lajkó, Dr. László Kőhidai

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

2925

Start

10:42

End

10:45

Authors (legacy)

Angela Takacs
Department of Genetics, Cell and Immunobiology, Budapest